Orion Portfolio Solutions LLC Grows Stock Holdings in Organon & Co. (NYSE:OGN)

Orion Portfolio Solutions LLC lifted its position in Organon & Co. (NYSE:OGN) by 237.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,025 shares of the company’s stock after buying an additional 25,365 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Organon & Co. were worth $537,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Horizon Bancorp Inc. IN grew its position in Organon & Co. by 2,401.5% in the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after acquiring an additional 1,585 shares in the last quarter. Millstone Evans Group LLC acquired a new position in shares of Organon & Co. in the fourth quarter valued at approximately $29,000. Larson Financial Group LLC increased its stake in Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after buying an additional 1,734 shares during the period. Riverview Trust Co lifted its holdings in Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after buying an additional 1,292 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after buying an additional 1,324 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Trading Down 3.9 %

OGN opened at $12.54 on Tuesday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a one year low of $12.15 and a one year high of $23.10. The company has a market cap of $3.23 billion, a P/E ratio of 3.76, a PEG ratio of 0.90 and a beta of 0.73. The business’s 50-day simple moving average is $15.08 and its 200-day simple moving average is $15.94.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, equities research analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 8.93%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Analyst Ratings Changes

A number of research firms have recently weighed in on OGN. Morgan Stanley cut their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, February 14th. TD Cowen raised Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Barclays lowered their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.80.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.